Proxima
New York
About Proxima
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach. Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $86.3M
- Funding stage: Seed
- Last round: Seed (Jan 2026)
- Website: proximabio.com
- Phone: +1 347 633 3580
Industries & Categories
Alternative Medicine, Artificial Intelligence (AI), Biotechnology, Clinical Trials, Life Science
Social Profiles
Canonical: https://fsome.com/organization/proxima-38288 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.